PDUFA Negotiations Begin With FDA Seeking Review System Reform
This article was originally published in The Tan Sheet
Executive Summary
During the inaugural negotiating session for renewal of PDUFA, which covers OTC switch and other nonprescription product NDAs, FDA says among its goals are “enhancements to the review processes.” The five-hour session included the ground rules for the talks and FDA and industry representatives also laid out their general wants and needs.
You may also be interested in...
CHPA Looks For FDA Reform Legislation To Deliver Monograph Changes In 2016
CHPA chief Scott Melville is optimistic for OTC monograph reform progress in 2016. In an interview about CHPA's 2016 priorities, Melville also said state and local environmental regulations that touch OTC drugs will garner attention.
CHPA Looks For FDA Reform Legislation To Deliver Monograph Changes In 2016
CHPA chief Scott Melville is optimistic for OTC monograph reform progress in 2016. In an interview about CHPA's 2016 priorities, Melville also said state and local environmental regulations that touch OTC drugs will garner attention.
PDUFA VI: BIO Survey Finds FDA Communication Problems
Data may help industry stake out its negotiating position as formal talks near for user fee reauthorization.